Oxymetazoline is a potent, long-acting, direct-acting sympathomimetic amine. It is a selective alpha-2 adrenergic receptor agonist with some alpha-1 activity. In the Indian context, it is primarily used as a topical nasal decongestant in the form of drops or sprays to provide rapid relief from nasal congestion associated with allergic rhinitis, common cold, and sinusitis. Its vasoconstrictive action is highly localized, making it a preferred choice for symptomatic relief.
Adult: 2-3 drops or 2-3 sprays (0.1% solution) into each nostril every 10-12 hours. DO NOT EXCEED 2 doses in 24 hours.
Note: 1. Blow nose gently to clear nostrils. 2. Tilt head slightly back. 3. Insert applicator tip into nostril, pointing away from the nasal septum. 4. Squeeze bottle or pump spray while breathing in gently through the nose. 5. Avoid contact of dropper/spray tip with nasal surfaces to prevent contamination. 6. Do not share the bottle. Use for a maximum of 3-5 consecutive days.
Oxymetazoline acts as a potent vasoconstrictor of the arterioles in the nasal mucosa. It stimulates postsynaptic alpha-2 adrenergic receptors in vascular smooth muscle, leading to activation of the G-protein coupled receptor, inhibition of adenylate cyclase, decreased intracellular cAMP, and subsequent smooth muscle contraction. This reduces blood flow to the engorged nasal turbinates and sinuses, leading to shrinkage of swollen mucous membranes and opening of nasal airways.
Pregnancy: Category C: Animal reproduction studies have shown an adverse effect, but there are no adequate and well-controlled studies in humans. Use only if the potential benefit justifies the potential risk to the fetus. Should be used sparingly and for the shortest duration possible.
Driving: Generally safe. However, if dizziness or blurred vision occurs, patients should avoid driving or operating machinery.
| Monoamine Oxidase Inhibitors (MAOIs) - e.g., Phenelzine, Tranylcypromine | Risk of severe, potentially fatal hypertensive crisis due to potentiation of pressor effects. | Contraindicated |
| Other Sympathomimetics (e.g., Pseudoephedrine, Phenylephrine oral) | Additive pressor effects, increasing risk of hypertension, tachycardia, and arrhythmias. | Major |
| Tricyclic Antidepressants (TCAs) - e.g., Amitriptyline | May potentiate the pressor effects of oxymetazoline. | Moderate |
| Beta-blockers (e.g., Propranolol) | Unopposed alpha-adrenergic stimulation may lead to severe hypertension and bradycardia. | Moderate |
| Ergot Alkaloids (e.g., Ergotamine) | Increased risk of severe vasoconstriction and ischemia. | Major |
Same composition (Oxymetazoline (0.1% w/v)), different brands: